HRA011585
Title:
An iPSC-derived CD19/BCMA-targeting CAR-NK therapy induced immune reset in refractory systemic sclerosis
Release date:
2025-05-21
Description:
This project reports the first clinical application of iPSC-derived, CD19/BCMA dual-targeting CAR-NK cells (QN-139b) for the treatment of severe diffuse cutaneous systemic sclerosis (dcSSc). The allogeneic product was extensively engineered to minimize immunogenicity and enhance in vivo efficacy, with scalable manufacturing enabled by clonal expansion of iPSCs. In the treated patient, QN-139b was well-tolerated and induced profound B cell depletion alongside marked clinical improvements, including reductions in fibrosis and autoantibody levels. Integrated multi-omics and histopathological analyses revealed immune modulation, reversal of fibrosis, and tissue regeneration. These findings position QN-139b as a promising cell-based immunotherapy for treatment-resistant autoimmune diseases.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
diffuse scleroderma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
iCAROMICS-dcSSc
Contact person:
Wang Xiaobing
Email:
gale820907@163.com
Description:
iCAROMICS-dcSSc represents the first human clinical multi-omics dataset generated from the treatment of diffuse cutaneous systemic sclerosis (dcSSc) using iPSC-derived, dual-targeting CAR-NK cells (QN-139b). This integrative resource comprises immune transcriptomic, proteomic, and histopathological data, offering mechanistic insights into therapy-induced immune remodeling, fibrosis resolution, and tissue regeneration.
Individuals & samples
Submitter:   Wang Xiaobing / gale820907@163.com
Organization:   Second Affiliated Hospital of Naval Medical University
Submission date:   2025-05-19
Requests:   3